title: Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.
authors.affiliation: Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX Stephen.Chun@UTSouthwestern.edu.
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Chun
authors.affiliation: Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Puneeth
authors.initials: P
authors.lastname: Iyengar
authors.affiliation: Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: David E
authors.initials: DE
authors.lastname: Gerber
authors.affiliation: University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Robert N
authors.initials: RN
authors.lastname: Hogan
authors.affiliation: Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Robert D
authors.initials: RD
authors.lastname: Timmerman
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001766:Blindness / Q000139:chemically induced*; D001932:Brain Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy / Q000556:secondary; D016371:Cranial Irradiation; D000077547:Crizotinib; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008279:Magnetic Resonance Imaging; D018908:Muscle Weakness / Q000209:etiology; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D009901:Optic Nerve Diseases / Q000139:chemically induced*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D015398:Signal Transduction / Q000187:drug effects; D014178:Translocation, Genetic / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib